Baird analyst Joel Beatty lowered the firm’s price target on Acadia Pharmaceuticals to $28 from $31 and keeps an Outperform rating on the shares. The firm said its Daybue revenue was a bit weak 1Q24, but they are encouraged that it appears to have been due to seasonality that it has already recovered.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACAD Earnings this Week: How Will it Perform?
- Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
- Acadia Pharmaceuticals to present trofinetide findings in Rett syndrome at AAN
- Largest borrow rate increases among liquid names
- Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan